MS Xevo G2 Q-Tof ESI+ 1 2 / pm-4 00 am 2 00 am # am # am #3 / pm am am #4 0.8 kv 20 V MS E ev MS E MASSLYNX

Similar documents
Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPL

LC LC ACQUITY UPLC H-Class ACQUITY UPLC CSH C mm 1.7 µm : THF/ 2/8 A 1 mm / 4/6 THF 2 mg/ml THF/ 2 THF 2 ACQUITY UPLC CSH C 18

HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HIL

ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB 3.

1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C) Thiamine (B1) Nicotinic Acid (B3) Pyridoxal (

UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC

[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2

2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP

LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY

:010_ :3/24/2005 3:27 PM :05/03/28 14:39

橡事例集表紙CD.PDF

pera1会社概要n

[ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1

LC/MS/MS によるフェノール類分析 日本ウォーターズ株式会社 2015 Waters Corporation 1 対象化合物 Cl HO HO HO フェノール 2- クロロフェノール (2-CPh) Cl 4-クロロフェノール (4-CPh) HO Cl HO Cl HO Cl Cl 2,4

DCR-PC300K/IPK

住まい・まちづくり活動事例集

Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B

表紙/宮副 森 森 森 柴田 芦塚

ERS-7

MassPREP Mix %TFA 0.1% mg/ml < 70%DFVGYGVKDFVGVGVK 0.1%TFA 0.1% 1 4 mg/ml 1 ml/min UV 20 µl/min MS LC ACQUITY UPLC H-Class Bio

untitled

clover-375.pdf

FMV-TEOシリーズ(2008年6月版)製品カタログ

1

untitled

PM9000C 開墾と据置作業を行われる方へ

本製品をご購入.indd

00_cover1_2.pm6

アプリケーションソフトウェアガイド PM2200C用




Made for Life Report 2008

Microsoft Outlook 2013

2 3

筆王 for NEC

JAJP.indd

Metabolomic Profiling_JA.qxp

*p _Œâ‡í‡ê‡é

2 of :30 PM

広報かわぐち 2005年2月号

研究紀要 第14号 (研究ノート1)

untitled

JSF_No.100



UX-V503CL/UX-V503CW

表紙




ドコモP-01Hカタログ

日本外傷歯学会認定医(平成24年11月30日付) H

P20・01/東 宮副 平島

P2_4/山道 芦塚 木下

薬物分析法の開発

untitled

北アルプス_燕岳~穂高_-2.doc

NL95„‹™èflÅ.p65

『こみの株式会社』の実践

,276 3,

EX-word_Library_JA

324.pdf

グローバリゼーションとイデオロギー(上)

1.4操作マニュアル+ユニット解説

0.3% 10% 4% 0.8% 5% 5% 23% 53%

1


low_ JAJP.qxd

MK14may_all.pdf

mr0805.indd

mr0605.indd

no May

広報2007年05月号-20p.indd

AC-2

エンジョイ北スポーツ

u u u 1 1


表紙_02




野岩鉄道の旅

1 No.236 HP TAXUS

EPSON PX-G920 基本操作ガイド







スタイルシェルフ 〈クローク収納プラン〉

2

<31332D97708CEA89F090E02E6D6364>

マイスタープロジェクト 推奨仕様

1

第18回海岸シンポジウム報告書

3

(718)


Transcription:

UPLC-Tof-MS E John Archer, 1 Paul Dargan, 1 David Wood, 1 Nayan Mistry, 2 and Michelle Wood 2 1 Guy s and St. Thomas NHS Foundation Trust, Clinical Toxicology, London, UK 2 Waters Corporation, MS Technologies Centre, Manchester, UK British Crime Survey 2010/2011 8.8 1 Dance magazine Mixmag MDMAcocaine mephedrone 50 75 2 41 1 mephedrone UPLC /Tof-MS E UPLC/Tof-MS E ACQUITY UPLC Xevo G2 Q-Tof TM ACQUITY UPLC HSS C18 Tof UPLC-Tof-MS E 1

MS Xevo G2 Q-Tof ESI+ 1 2 / 11 00 pm-4 00 am 2 00 am #1 3 00 am #2 4 00 am #3 / 11 00 pm-10 00 am 10 00 am #4 0.8 kv 20 V MS E 10-40 ev MS E MASSLYNX Targetlynx TM ChromaLynx TM Posi ive TM 5 UPLC ACQUITY UPLC ACQUITY UPLC HSS C18 2.1 x 150 mm 1.8 µm 186003534 50 10 10 µl A B 5 mm (ph 3.0) 0.1% A B 400 µl/min 15 UPLC-Tof-MS E 2

A Waters Xevo G2 Q-Tof MS E 1 1000 RT 75 4 4 74 4 B Potential adulterants C 1 MS E A-C 4-fluoroamphetamine(4-FA) MS E - 2 A T-Wave TM B C UPLC-Tof-MS E 3

4 1 Amphetamine + Cocaine + Ketamine + Methamphetamine Morphine MDMA + Mephedrone (4-MMC) + NRG-2 (4-MEC) 2-AI TFMPP + 1 4 Diltiazem levamisole caffeine lidocaine quinine Potential adulterants OTC 2 #2 MS E Mephedrone (4-methylmethcathinone) amphetamine (MDMA MDA methamphetamine) cocaine ketamine paracetamol levamisole atazanavir nevirapine UPLC-Tof-MS E 4

Xevo G2 Q-Tof 1000 1. Smith K, Flatley J. Drug misuse declared: findings from the 2010/2011 British Crime Survey. HOSB (2011). http://www.homeoffice.gov.uk/publications/ science-research-statistics/research-statistics/home-office-science/ consult-drug-misuse-12?view=standard&pubid=1033970 (last accessed 25th May 2012). 2. Winstock A. Drugs survey. Mixmag. 2011; 238: 50-59. 3. Archer JRH, Dargan PL, Hudson S, Davies S, Puchnarewicz M, Kicman AT, Ramsey J, Measham F, Wood M, Johnston A, Wood DM. Taking the pissoir-a novel way of knowing what drugs are being used in the nightclubs. Submitted to Journal of Substance Abuse. www.waters.com 140-0001 1-3-12 5 TEL 03-3471-7191 FAX 03-3471-7118 532-0011 5-14-1011F TEL 06-6304-8888 FAX 06-6300-1734 Waters ACQUITY UPLC Xevo UPLC MassLynx Waters Corporation Q-Tof T-Wave TargetLynx ChromaLynx Posi ive The Science of What s Possible Waters Corporation 2013 Waters Corporation. Printed in Japan. 2013 6 720004583JA PDF